Ozmosi | Lisuride Drug Profile

Product Description

Mechanisms of Action: D2 Agonist, D3 Agonist, D4 Agonist, 5-HT1A Agonist, 5-HT2A Agonist, 5-HT2B Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Subcutaneous, Transdermal

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Axxonis Pharma AG
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Parkinson's Disease|Restless Legs Syndrome|Psychomotor Agitation

Phase 2: Parkinson's Disease|Hypertension, Pulmonary

Phase 1: Cocaine-Related Disorders

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00000338	Lisuride	P1	Unknown status	Cocaine-Related Disorders	None	2019-03-21	Treatments
2012-001675-37	Lis-Safe	P2	Terminated	Hypertension, Pulmonary	2014-08-19	2022-03-13	Treatments
NCT00089622	04-N-0258	P2	Completed	Parkinson's Disease	None	2019-03-21	Treatments
2005-001006-12	CALIPSO	P3	Completed	Parkinson's Disease	2009-10-02	2022-03-12	Treatments
2006-003732-30	TULEP 1	P3	Active, not recruiting	Parkinson's Disease	2008-09-20	2025-06-19	Treatments
2005-003549-16	Tulir03/01	P3	Active, not recruiting	Restless Legs Syndrome	2007-09-08	2025-06-25	Treatments
2004-001589-42	2004-001589-42	P3	Active, not recruiting	Restless Legs Syndrome	2006-08-25	2022-03-12	Treatments
NCT00408915	CALIPSO	P3	Completed	Parkinson's Disease	None	2019-03-21	Treatments
NCT00367822	Transdermal Lisuride	P3	Completed	Restless Legs Syndrome\|Psychomotor Agitation	None	2019-03-21	Treatments

Recent News Events

Date	Type	Title
04/16/2024	PubMed	Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model.
03/01/2024	PubMed	Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?
02/05/2024	PubMed	Comparative Pharmacological Effects of Lisuride and Lysergic Acid Diethylamide Revisited.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Lisuride

Alternative Names: lisuride, dopergin Clinical Status: Inactive Latest Update: 2024-04-16 Latest Update Note: PubMed Publication